MO in #PDAC at #ESMO24 (2/2) Phase II trial; 63 pts Maintenance Pembro+Olaparib in 3 selected cohorts of patients 1 – HRD 2 – ncHRD 3 –exceptional platinum responders Promising activity seen (1 > 2 > 3) Discussion by Arndt Vogel 👏🏻 ESMO - Eur. Oncology #ESMOAmbassadors Grupo Español de Tratamiento de Tumores Digestivos

Nice international collaboration on #HER2 and biliary tract cancer. Great work Dr. Mondaca Memorial Sloan Kettering Cancer Center trials ongoing for patients with Her2 positive BTC

Interesting data of high relevance to the care of patients with cancer. Many implications to the focus of our clinical trial efforts at Simmons. ascopubs.org/doi/10.1200/JC…

🚨 NEW: A study published in @nature overseen by MSK's Karuna Ganesh and dana_peer illuminates differences between primary & metastatic #colorectalcancer. Researchers say understanding the differences may lead to new therapeutic opportunities. Learn more: bit.ly/4hmIh1z

🎉 Progress for Patients🎉 The FDA has granted accelerated approval for Jazz Pharmaceuticals' treatment for adults with previously treated, unresectable, or metastatic HER2-positive (IHC3+) biliary tract #cancer. This milestone offers new hope to patients and highlights the

Congratulations Rohit Thummalapalli MSK Department of Medicine Memorial Sloan Kettering Cancer Center Ghassan Abou-Alfa

Treatment Innovation in #BiliaryTractCancer: Gain insights into biomarker testing, guidelines, & the safety and efficacy for BTC treatment platform with Drs. Arndt Vogel, James J. Harding, MD, & Ghassan Abou-Alfa. 1/23 at 6:00 PM PST. Produced with Cholangiocarcinoma Foundation. bit.ly/Biliary-SF25T #ASCOGI2025

Starting at 11:30 a.m. PST: ASCO #GI25 poster sessions! Stop by the West Hall for #pancreaticcancer and #biliarytractcancer advances by James J. Harding, MD, Eileen M O’Reilly, Rohit Thummalapalli, Layal Al Mahmasani, and more! @mskcancercenter bit.ly/3WB5q7J

Front row for opening session and soaking in all the content at the #SSOACT25 with friends from Memorial Sloan Kettering Cancer Center | Amazing scientific program this year spanning all advanced cancer therapies | Kevin Soares Society of Surgical Oncology Duke Surgical Oncology

Real global collaboration in academia. Really delightful experience. This is the reason I work in academia. Thanks Arndt Vogel

🔥CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer🔥 👉based on HERIZON-BTC: ORR 41% 👉Phs-III in 1st line ongoing ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation @livertwitter

Excited to speak w/ Arndt Vogel & Teresa Macarulla at a PeerView BTC symposium on May 30 during #ASCO25! Cholangiocarcinoma Foundation bit.ly/BiliaryT

#ASCO2025 Not a GI cancer (I know, I know)... but this ADC may be heading to GI settings soon 👀 Temab-A (c-Met mAb + topo I payload) in 3L+ EGFR MT NSQ NSCLC shows serious activity n = 41 🎯 ORR: 63% ✅ Clinical Benefit Rate: 83% 📊 PFS @ 6 mo: 80% 📊 OS @ 6 mo: 93% 🧬 Responses

BTC care just got more personalized—let’s unpack it at our PeerView session. See you tonight May 30! Arndt Vogel Teresa Macarulla Cholangiocarcinoma Foundation bit.ly/BiliaryT

Incredible conversations, powerful partnerships, and shared commitment to advancing cholangiocarcinoma research and care. We were proud to represent the cholangiocarcinoma community at #ASCO25 and connect with those driving progress forward.

See a new #biliarycancer activity via PeerView Arndt Vogel James J. Harding, MD Teresa Macarulla #ASCO #Oncology #MedEd lrn.peerview.com/150210490_1_we…

Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨 buff.ly/KVngjav Join leading experts for two days of case-based learning, interactive panels, and

Expert faculty from Memorial Sloan Kettering Cancer Center will join the stage at Great Debates in Solid Tumors this September. From gastrointestinal to lung to women’s cancers, they will bring MSK perspectives to the debates where new data and differing viewpoints are shaping how clinicians approach

Looking forward to debate #HCC #livercancers treatment and learn about status of field tomorrow! Great Debates #miami Yelena Y. Janjigian MD

Last #GI debate of the day Great Debates #GDST with Dr. Olatunji Alese Winship Cancer Institute of Emory University with James J. Harding, MD Memorial Sloan Kettering Cancer Center re: choice of #Immunotherapy in #HCC. 👏 👏 #newfriends Best part about in person meetings. 😁 #cancer #cancerresearch 🙏🏻 Yelena Y. Janjigian MD